![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Biol Chem, Vol. 275, Issue 20, 14783-14786, May 19, 2000
,From the Laboratory of Immunobiology, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702
| |
ABSTRACT |
|---|
|
|
|---|
Cooperation between integrins and growth factor
receptors plays an important role in the regulation of cell growth,
differentiation, and survival. The function of growth factor receptor
tyrosine kinases (RTKs) can be regulated by cell adhesion to
extracellular matrix (ECM) even in the absence of ligand. We
investigated the pathway involved in integrin-mediated RTK activation,
using RON, the receptor for macrophage-stimulating protein. Adhesion of
RON-expressing epithelial cells to ECM caused phosphorylation of RON,
which depended on the kinase activity of both RON itself and c-Src.
This conclusion is based on these observations: 1) ECM-induced RON
phosphorylation was inhibited in cells expressing kinase-inactive
c-Src; 2) active c-Src could phosphorylate immunoprecipitated RON from
ECM-stimulated cells but not from unstimulated cells; and 3) ECM did
not cause RON phosphorylation in cells expressing kinase-dead RON, nor
could active c-Src phosphorylate RON immunoprecipitated from these
cells. The data fit a pathway in which ECM-induced integrin aggregation causes both c-Src activation and RON oligomerization followed by RON
kinase-dependent autophosphorylation; this results in RON becoming a target for activated c-Src, which phosphorylates additional tyrosines on RON. Integrin-induced epidermal growth factor receptor (EGFR) phosphorylation also depended on both EGFR and c-Src kinase activities. This sequence appears to be a general pathway for integrin-dependent growth factor RTK activation.
Growth, differentiation, and survival of
anchorage-dependent cells are regulated through signals
generated by adhesion to ECM1
and by soluble growth factors (1-5). Cell-matrix interaction is
mediated by integrins, transmembrane noncovalently linked heterodimeric receptors consisting of As to the basis for their collaboration, integrins and growth factor
receptors may form macromolecular complexes on the cell membrane (7, 8,
13, 16-18). In that case, adhesion-induced aggregation of integrins
might trigger co-aggregation (5) and autophosphorylation of growth
factor RTKs (13). Integrin-induced epidermal growth factor (EGF) and
platelet-derived growth factor (PDGF) RTK phosphorylation depends on
the kinase activity of the receptor (7, 13). Recent data suggest that
integrin association with RTKs might also protect the latter against
the activity of phosphatases (17, 19) and/or ensure the correct
subcellular juxtaposition of cytoplasmic tails of dimerized growth
factor receptors (17). Despite the cited progress in this area of
research, the molecular mechanisms underlying growth factor receptor
activation by integrins remain to be defined.
RON is an RTK that mediates the biological effects of
macrophage-stimulating protein (MSP) (20, 21). MSP was discovered as a
serum factor that regulates the motility of macrophages (22). Recent
investigations have shown that the RON receptor is expressed in various
cell types including epithelial cells (23) and that MSP-mediated
effects on epithelial cells are integrin-dependent (23,
24). In the present work, we investigated the pathway involved in
integrin-mediated activation of RON.
Site-directed Mutagenesis of the RON Receptor--
A kinase-dead
K1114M RON mutant was generated using the GeneEditor (Promega, Madison,
WI) mutagenesis kit with oligonucleotide GTGCCATCATGTCACTAAG.
Cells and Transfections--
RE7 (20) (MDCK RON-expressing
cells), MDCK, and HEK 293 cells (ATCC, Manassas, VA) were grown in DMEM
with 10% FCS. HaCat cells (donated by Dr. N. Fusenig, Heidelberg,
Germany) were grown in KSF medium with supplements.
For transient transfection of the HEK 293 cell line, cells were grown
to 70-80% confluence on 15-cm dishes and transfected with 20 µg of
RON cDNA or empty vector pCI-neo (Promega, Madison, WI) using
Superfect reagent (Qiagen, Santa Clarita, CA). For co-transfection, 10 µg of RON cDNA plus 10 µg of empty vector (MOCK), FAK Y397F, or
dominant-negative (dn) c-Src (K295M/Y527F) mutant DNAs were used.
For transient transfection of MDCK cells, 15 µg of empty vector or dn
c-Src were co-transfected together with 5 µg of MACS4 plasmid
(Miltenyi Biotec, Auburn, CA) using Superfect reagent. After
36 h, successfully transfected cells were selected using a MACS4
selection kit (Miltenyi Biotec).
Cell Stimulation, Lysis, Immunoprecipitation, and Western
Blotting--
Cells were starved overnight in medium without serum and
then collected from dishes and stimulated with 5 nM MSP
(Toyobo, Japan) or 50 µg/ml EGF (Life Technologies, Inc.) for 30 min
in suspension or on noncoated or poly-lysine-coated dishes. For
stimulation by ECM (mouse collagen type IV, human collagen type I, or
human fibronectin), cells were plated on ECM-coated dishes in the
presence or absence of 5 nM MSP or 50 µg/ml EGF for 30 min. After stimulation, cells were lysed in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF, 1% Triton
X-100, 10 µg/ml leupeptin, 10 units/ml aprotinin, 1 mM
phenylmethylsulfonyl fluoride). Insoluble material was removed by
centrifugation, and RON receptor was immunoprecipitated from
supernatants using mouse monoclonal anti-RON antibodies (clone ID2).
RON tyrosine phosphorylation was detected by Western blotting using
anti-phosphotyrosine antibodies (anti-PY, clone 4G10, Upstate Biotechnology, Inc., Lake Placid, NY). Rabbit anti-RON antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used for detection of
RON on the membranes.
RON Kinase Assay in Vitro--
RON was immunoprecipitated from
cell lysates by RON antibodies. Immunoprecipitates were washed twice in
HNTG buffer (50 mM HEPES, pH 7.4, 150 mM NaCl,
0.1% Triton X-100, 10% glycerol) and twice in kinase buffer (20 mM HEPES, pH 7.4, 10% glycerol, 10 mM
MgCl2, 10 mM MnCl2, 150 mM NaCl). To initiate kinase reactions, 15 µCi of
[ Phosphorylation of RON by c-Src in Vitro--
Pure
constitutively active c-Src enzyme (3 units/sample; Upstate
Biotechnology, Inc.) was incubated with immunoprecipitated RON and 15 µCi of [ Assay of Cell Accumulation in Tissue Culture--
RE7 cells
(MDCK cells stably expressing the RON receptor, 1 × 104 cells/well) were plated in triplicate into 96-well
tissue culture plates, uncoated (control) or coated with mouse collagen
type IV, and incubated in the presence or absence of 1 nM
MSP in DMEM without FCS. Cell numbers were measured after 48 h by
adding 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) into culture wells and measuring A570
2 h later. The number of cells was determined from an MTT
calibration curve for this cell line.
In the present work, we investigated the effect of
integrin-dependent adhesion on the functional activity of
RON and the molecular mechanisms mediating this effect. Plating of
RON-expressing HEK 293 epithelial cells on a collagen-coated substrate
induced ligand-independent RON tyrosine phosphorylation (Fig.
1A, lane 3) and
kinase activity (Fig. 1B, lane 3). The Addition of MSP to
collagen-adherent cells caused a higher level of RON phosphorylation
and kinase activity than either MSP or collagen alone (Fig. 1,
A and B). The time courses of RON phosphorylation
induced by these different stimuli were comparable, with a plateau at
about 30 min (data not shown). RGD-containing peptide or
anti-
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
and
subunits (6). Integrin engagement by ECM can modulate growth factor signaling pathways, increasing the
activity of growth factor RTKs (7, 8) and their downstream intracellular mediators (9, 10). Integrin-based effects on growth
factor receptors include enhancement of cell migration (11, 12),
survival (13), and proliferation (14-17).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
32P]ATP (3000 Ci/mmol, 10 µCi/ml) was added, and
immunoprecipitates were incubated for 30 min at room temperature in 15 µl total volume. The exogeneous substrate, myelin basic protein
(MBP), was added to the kinase reaction mixture at a concentration of
0.5 µg/reaction tube. Reactions were stopped with 5 µl of 4×
sample buffer. Phosphorylated RON or its substrate, MBP, were
visualized after SDS-PAGE by autoradiography.
32P]ATP (3000 Ci/mmol, 10 µCi/ml) in
kinase buffer for 30 min at room temperature, and incorporation of
32P into RON was detected by autoradiography after
SDS-PAGE.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1-integrin antibodies blocked ECM-induced RON
activation (data not shown), indicating that the effect of ECM
(collagen types I and IV, fibronectin) on RON phosphorylation and
activation is mediated by integrins. Similar results were obtained with
MDCK cells stably expressing transfected RON and with the human HaCat
keratinocyte cell line that expresses endogenous RON (data not shown).
In addition to the effect on RON phosphorylation and kinase activity,
the combination of MSP and ECM maximized epithelial cell numbers,
measured after 48 h in culture (Table I). Effects of ECM, alone or with growth
factor, on receptor phosphorylation or downstream mediators have been
described for Met (25), EGF (7, 8, 13-16), PDGF (7, 8, 16), fibroblast growth factor (8), VEGFR-2 (17), and insulin (16) receptors in various
cell types, indicating that cell-ECM interactions frequently regulate
growth factor-RTK responses.

View larger version (34K):
[in a new window]
Fig. 1.
Stimulus-induced tyrosine phosphorylation and
kinase activity of RON transiently expressed in HEK 293 cells.
Cells in serum-free medium were stimulated in suspension with 5 nM MSP or plated on mouse collagen IV (Col
IV)-coated dishes in the presence of MSP or medium alone for 30 min. Cells were then lysed, and RON was immunoprecipitated from the
lysates for detection of tyrosine phosphorylation or kinase activity.
A, RON tyrosine phosphorylation was detected by Western
blotting with anti-phosphotyrosine (WB: PY) antibodies. The
level of RON phosphorylation was calculated by densitometry of the
phosphorylated RON bands on the blots and expressed as a percent of the
RON phosphorylation level induced by the combination of MSP and
collagen IV. Bar graph data are means ± S.E. of three independent
experiments. The upper blot shows results of a
representative experiment demonstrating the levels of RON
phosphorylation. The lower blot, developed with anti-RON, is
a control for the amount of RON in precipitates. The two bands
represent immature (upper band) and mature RON (lower
band). B, RON kinase activity was assayed in
vitro using [32P]ATP and MBP as substrates. The
level of RON kinase activity was calculated by densitometry of the
phosphorylated MBP bands on the autoradiographs and expressed as a
percent of the MBP phosphorylation induced by the combination of MSP
and collagen IV. Bar graph data are means ± S.E. of three
independent experiments. The autoradiograph shows results of one
experiment demonstrating incorporation of 32P into
MBP.
Effect of collagen type IV on MSP-induced accumulation of RE7 (MDCK
RON-expressing) cells
In thinking about a molecular mechanism mediating the ECM effect on
RON, we considered two possibilities, which are not mutually exclusive.
1) Inasmuch as RON is associated with
1 integrin (24), ECM-induced integrin aggregation could result in RON oligomerization, transphosphorylation, and increased RON kinase activity; and (2) tyrosine kinases activated by integrins might phosphorylate and activate RON.
Two tyrosine-specific cytoplasmic kinases, focal adhesion kinase (FAK)
and c-Src, can be activated in response to cell-ECM adhesion (26). Cell
adhesion to ECM induces integrin aggregation and activation of FAK,
which is associated with
integrin. The initial step in FAK
activation is transphosphorylation of Tyr397, after which
c-Src can bind phosphorylated Tyr397 via its SH2 domain
(27). This interaction between FAK and c-Src increases c-Src kinase
activity. Activation of FAK and c-Src is a key point in
integrin-mediated signal transduction (26).
To study the role of FAK in integrin-mediated RON phosphorylation, we
co-expressed transiently wild type RON with the major autophosphorylation site (Y397F) FAK mutant in HEK 293 cells. In cells
expressing the Y397F FAK mutant, the level of collagen-induced RON
phosphorylation was about one-half that of cells transfected with
vector alone (Fig. 2A). The
fact that the FAK Y397F mutant decreased ECM-induced RON
phosphorylation suggested the involvement of c-Src, a downstream
kinase, for which FAK-phosphorylated Tyr397 is a binding
site (27).
|
To test for a role of c-Src in ECM-induced RON phosphorylation, we transfected HEK 293 cells with a dn kinase-inactive c-Src construct. Collagen-induced RON phosphorylation (Fig. 2B) in these cells was reduced comparable with the Y397F FAK mutant (Fig. 2A). These data were consistent with the postulated ECM-integrin-FAK-c-Src pathway, suggesting that RON is phosphorylated by activated c-Src.
We therefore determined the capacity of c-Src to phosphorylate RON
in vitro by adding active purified c-Src enzyme to RON immunoprecipitated from HEK 293 cells. These cells were also
transfected with the kinase-inactive c-Src construct, in addition to
RON, to prevent possible in vivo c-Src activity. RON was
immunoprecipitated from cells that were either unstimulated or
stimulated with MSP or collagen. Active c-Src in vitro
phosphorylated RON from collagen-stimulated cells but failed to
phosphorylate RON from unstimulated or MSP-stimulated cells (Fig.
3). These results indicate that c-Src can
phosphorylate RON but that sites become available for phosphorylation
by c-Src only on RON from cells stimulated with ECM. In contrast to our findings, it has been reported that c-Src can phosphorylate
nonstimulated or ligand-stimulated growth factor receptors (28-30);
these published results are with cultured adherent cells, the integrins
of which might be engaged by fibronectin derived from cells or
serum.
|
Fig. 3 also shows that although MSP alone does not make RON a target for phosphorylation by c-Src, it enhances the response to collagen. This apparent synergy between MSP and collagen in making RON a target for c-Src might be the result of increased RON kinase activity (Fig. 1B, last bar).
How does stimulation by ECM make RON a target for c-Src? A clue was provided by the fact that expression of either Y397F FAK or kinase-inactive c-Src only partially decreased ECM-induced RON phosphorylation (Figs. 2 and 3), suggesting that a kinase distinct from FAK and c-Src is involved in ECM-induced RON phosphorylation. We considered the possibility that RON itself might play that role. To test whether RON kinase activity was required for ECM-mediated RON phosphorylation, we expressed a kinase-dead RON (RONkd) construct in HEK 293 cells. Stimulation of RONkd-293 cells with MSP or collagen did not cause RON phosphorylation (data not shown). Moreover, active purified c-Src in vitro did not phosphorylate RONkd immunoprecipitated from collagen- or MSP-stimulated cells (data not shown), which is additional evidence that nonphosphorylated RON is not a substrate for c-Src. Thus, RON kinase activity is essential for ECM-mediated effects on RON. This finding correlates with observations that PDGF (7) and EGF (13) receptor kinase activity is necessary for ECM-induced receptor phosphorylation.
Our results suggest that ECM-induced RON phosporylation and activation
occur in two steps. Step 1: because RON is associated with
1 integrin (24), ECM-induced integrin aggregation can lead to RON oligomerization and transphosphorylation, which causes an increase in RON kinase activity above the basal level that initiates
the autophosphorylation. Step 2: RON molecules phosphorylated in step 1 are a target for c-Src activated via the ECM-integrin-FAK pathway,
which results in the phosphorylation of additional tyrosines on RON.
Data consistent with step 1 are the requirement for RON kinase activity
for the ECM effect (no ECM effect on cells with RONkd) and ECM-induced
RON phosphorylation above unstimulated levels in cells with step 2 blocked by kinase-inactive c-Src (Fig. 3). Data consistent with step 2 are prevention of the additional increment of ECM-induced
phosphorylation in cells with kinase-inactive c-Src (Fig. 3), and
phosphorylation in vitro by active c-Src of RON from
ECM-adherent cells but not from unstimulated cells.
We also found that adhesion to ECM by epithelial cells expressing
endogenous EGFR caused ligand-independent EGFR tyrosine phosphorylation
as well as increased EGF-dependent tyrosine phosphorylation (Fig. 4A). In agreement with
our data for RON, ECM-mediated phosphorylation of the EGFR requires
kinase activity of both the EGFR itself and c-Src. Inhibition of EGFR
kinase activity by tyrphostin blocked both EGF- and ECM-induced EGFR
phosphorylation (Fig. 4A). In contrast, inhibition of
endogeneous c-Src kinase activity by overexpression of kinase-inactive
c-Src had no effect on EGF-induced phosphorylation, but it prevented
the collagen-mediated increment (Fig. 4B). Thus, it appears
that ECM-induced EGFR phosphorylation occurs via the pathway outlined
above for RON, where EGFR catalytic activity and autophosphorylation
are essential for c-Src to phosphorylate additional tyrosines on EGFR.
Potentiation by c-Src of the mitogenic and tumorigenic capacity of EGFR
is mediated by phosphorylation of additional tyrosines in EGFR by
c-Src, when c-Src interacts with phosphorylated EGFR (29). The fact
that receptor phosphorylation induced by ECM-dependent
adhesion occurs via similar pathways for both RON and EGFR, which
belong to different growth factor receptor kinase families, suggests
that this is a common pathway that integrins may use for regulation of
growth factor RTK activity.
|
The nature of this regulation is a subject for further investigation.
The fact that c-Src can phosphorylate RON from cells stimulated by ECM,
but not by MSP (Fig. 3B), is evidence that the pattern of
RON tyrosine phosphorylation induced by ECM is distinct from that
induced by MSP. There are 14 tyrosines in the cytoplasmic domain of
RON. The similarity among the columns of Fig. 1, A and
B, suggests that incremental increases in phosphorylation of
some of these tyrosines may correlate with increments in RON kinase
activity. It is also possible that ECM or MSP stimulation results in
phosphorylation of different tyrosines, which could be unique docking
sites for particular downstream mediators. This could result in
different cellular responses, depending on whether RON was stimulated
by ECM or MSP. An example is the fact that epithelial cells cultured in
serum-free medium in collagen-coated dishes become apoptotic, despite
stimulation of RON by ECM adherence; and yet stimulation of RON in the
presence of MSP in these cultures prevents the apoptosis (31). Our next
step in this investigation will therefore be to determine whether
stimulation by ECM and MSP results in phosphorylation of different
tyrosines in the RON cytoplasmic domain.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. N. Fusenig (Heidelberg, Germany) for the HaCat keratinocyte cell line, Dr. D. Schlaepfer (Scripps Research Institute, La Jolla, CA) for mouse FAK mutant cDNAs, Dr. P. Schwarzberg (National Institutes of Health, Bethesda, MD) for the chicken c-Src mutant cDNAs, Dr. R. Breathnach (INSERM U211, Nantes Cedex 01, France) for human RON cDNA, Dr. F. A. Montero-Julian (Immunotech, Nantes Cedex 01, France) for mouse monoclonal anti-RON antibodies, Drs. B. Zbar (NCI-Frederick Cancer Research and Development Center, Frederick, MD), M. Andreazzoli (National Institutes of Health, Bethesda, MD), and S. Makarov (University of North Carolina, Chapel Hill) for useful discussions, and Dr. A. Miagkov (Johns Hopkins University, Baltimore, MD) for help in preparing the figures.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Laboratory of
Immunobiology, Bldg. 560, Rm. 1246, NCI-Frederick Cancer Research and
Development Center, Frederick, MD 21702. Tel.: 301-846-1560; Fax:
301-846-6145; E-mail: danilkovitch@mail.ncifcrf.gov.
Published, JBC Papers in Press, March 15, 2000, DOI 10.1074/jbc.C000028200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: ECM, extracellular matrix; dn, dominant-negative; DMEM, Dulbecco's modified Eagle's medium; EGF, epidermal growth factor; EGFR, EGF receptor; FAK, focal adhesion kinase; FCS, fetal calf serum; MBP, myelin basic protein; MDCK, Madin-Darby canine kidney cells; MSP, macrophage-stimulating protein; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; PDGFR, platelet-derived growth factor receptor; RTK, receptor tyrosine kinase; PAGE, polyacrylamide gel electrophoresis; RON, "recepteur d'origine Nantais"; RONkd, kinase-dead RON; RONwt, wild type RON.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Porter, J. C., and Hogg, N. (1998) Trends Cell Biol. 8, 390-396 |
| 2. | Juliano, R. (1996) BioEssays 18, 911-917 |
| 3. | Schwartz, M. A. (1997) J. Cell Biol. 139, 575-578 |
| 4. | Schwartz, M. A., and Baron, V. (1999) Curr. Opin. Cell Biol. 11, 197-202 |
| 5. | Giancotti, F. G., and Ruoslahti, E. (1999) Science 285, 1028-1032 |
| 6. | Hynes, R. O. (1992) Cell 69, 11-25 |
| 7. | Sundberg, C., and Rubin, K. (1996) J. Cell Biol. 132, 741-752 |
| 8. | Miyamoto, S., Teramoto, H., Gutkind, J. S., and Yamada, K. M. (1996) J. Cell Biol. 135, 1633-1642 |
| 9. | Renshaw, M. W., Ren, X. D., and Schwartz, M. A. (1997) EMBO J. 16, 5592-5599 |
| 10. | Aplin, A. E., and Juliano, R. L. (1999) J. Cell Sci. 112, 695-706 |
| 11. | Woodard, A. S., Garcia-Cardena, G., Leong, M., Madri, J. A., Sessa, W. C., and Languino, L. R. (1998) J. Cell Sci. 111, 469-478 |
| 12. | Li, J., Lin, M. L., Wiepz, G. J., Guadarrama, A. G., and Bertics, P. J. (1999) J. Biol. Chem. 274, 11209-11219 |
| 13. | Moro, L., Venturino, M., Bozzo, C., Silengo, L., Altruda, F., Beguinot, L., Tarone, G., and Defilippi, P. (1998) EMBO J. 17, 6622-6632 |
| 14. | Cybulsky, A. V., McTavish, A. J., and Cyr, M. D. (1994) J. Clin. Invest. 94, 68-78 |
| 15. | Jones, P. L., Crack, J., and Rabinovitch, M. (1997) J. Cell Biol. 139, 279-293 |
| 16. | Schneller, M., Vuori, K., and Ruoslahti, E. (1997) EMBO J. 16, 5600-5607 |
| 17. | Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., and Bussolino, F. (1999) EMBO J. 18, 882-892 |
| 18. | Plopper, G. E., McNamee, H. P., Dikem, L. E., Bojanowski, K., and Inberg, D. E. (1995) Mol. Biol. Cell 6, 1349-1365 |
| 19. | DeMali, K. A., Balciunaite, E., and Kazlauskas, A. (1999) J. Biol. Chem. 274, 19551-19558 |
| 20. | Wang, M.-H., Ronsin, C., Gesnel, M.-C., Coupey, L., Skeel, A., Leonard, E. J., and Breathnach, R. (1994) Science 266, 117-119 |
| 21. | Gaudino, G., Follenzi, A., Naldini, L., Collesi, C., Santoro, M., Gallo, K. A., Godowski, P. J., and Comoglio, P. M. (1994) EMBO J. 13, 3524-3532 |
| 22. | Leonard, E. J., and Skeel, A. (1976) Exp. Cell Res. 102, 434-438 |
| 23. | Wang, M.-H., Iwama, A., Dlugosz, A. A., Sun, Y., Skeel, A., Yuspa, S. H., Suda, T., and Leonard, E. J. (1996) Exp. Cell Res. 226, 39-46 |
| 24. | Danilkovitch, A., Skeel, A., and Leonard, E. J. (1999) Exp. Cell Res. 248, 575-582 |
| 25. | Wang, R., Kobayashi, R., and Bishop, J. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8425-8430 |
| 26. | Hanks, S. K., and Polte, T. R. (1997) BioEssays 19, 137 |
| 27. | Eide, B. L., Turck, C. W., and Escobedo, J. A. (1995) Mol. Cell. Biol. 15, 2819-2827 |
| 28. | Peterson, J. E., Kulik, G., Jelinek, T., Reuter, C. W., Shannon, J. A., and Weber, M. J. (1996) J. Biol. Chem. 271, 31562-31571 |
| 29. | Tice, D. A., Biscardi, J. S., Nickles, A. L., and Parsons, S. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1415-1420 |
| 30. | Biscardi, J. S., Maa, M. C., Tice, D. A., Cox, M. E., Leu, T. H., and Parsons, S. J. (1999) J. Biol. Chem. 274, 8335-8343 |
| 31. | Danilkovitch, A., Donley, S. M., Skeel, A., and Leonard, E. J. (2000) Mol. Cell. Biol. 20, 2218-2227 |
This article has been cited by other articles:
![]() |
S. Matsuzaki, M. Canis, J.L. Pouly, P. Dechelotte, K. Okamura, and G. Mage The macrophage stimulating protein/RON system: a potential novel target for prevention and treatment of endometriosis Mol. Hum. Reprod., May 1, 2005; 11(5): 345 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Camp, W. Liu, F. Fan, A. Yang, R. Somcio, and L. M. Ellis RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis Ann. Surg. Oncol., April 1, 2005; 12(4): 273 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Bill, B. Knudsen, S. L. Moores, S. K. Muthuswamy, V. R. Rao, J. S. Brugge, and C. K. Miranti Epidermal Growth Factor Receptor-Dependent Regulation of Integrin-Mediated Signaling and Cell Cycle Entry in Epithelial Cells Mol. Cell. Biol., October 1, 2004; 24(19): 8586 - 8599. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Wang, X. Zhang, and J. E. Groopman Activation of Vascular Endothelial Growth Factor Receptor-3 and Its Downstream Signaling Promote Cell Survival under Oxidative Stress J. Biol. Chem., June 25, 2004; 279(26): 27088 - 27097. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Angeloni, A. Danilkovitch-Miagkova, A. Miagkov, E. J. Leonard, and M. I. Lerman The Soluble Sema Domain of the RON Receptor Inhibits Macrophage-stimulating Protein-induced Receptor Activation J. Biol. Chem., January 30, 2004; 279(5): 3726 - 3732. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Wang, D. Wang, and Y.-Q. Chen Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase Carcinogenesis, August 1, 2003; 24(8): 1291 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lutz and P. H. Correll Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C {zeta} J. Leukoc. Biol., June 1, 2003; 73(6): 802 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Danilkovitch-Miagkova, F.-M. Duh, I. Kuzmin, D. Angeloni, S.-L. Liu, A. D. Miller, and M. I. Lerman Hyaluronidase 2 negatively regulates RON receptor tyrosine kinase and mediates transformation of epithelial cells by jaagsiekte sheep retrovirus PNAS, April 15, 2003; 100(8): 4580 - 4585. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Popsueva, D. Poteryaev, E. Arighi, X. Meng, A. Angers-Loustau, D. Kaplan, M. Saarma, and H. Sariola GDNF promotes tubulogenesis of GFR{alpha}1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase J. Cell Biol., April 14, 2003; 161(1): 119 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Reinhold, H. Kouros-Mehr, K. W. Kohn, A. K. Maunakea, S. Lababidi, A. Roschke, K. Stover, J. Alexander, P. Pantazis, L. Miller, et al. Apoptotic Susceptibility of Cancer Cells Selected for Camptothecin Resistance: Gene Expression Profiling, Functional Analysis, and Molecular Interaction Mapping Cancer Res., March 1, 2003; 63(5): 1000 - 1011. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Moro, L. Dolce, S. Cabodi, E. Bergatto, E. B. Erba, M. Smeriglio, E. Turco, S. F. Retta, M. G. Giuffrida, M. Venturino, et al. Integrin-induced Epidermal Growth Factor (EGF) Receptor Activation Requires c-Src and p130Cas and Leads to Phosphorylation of Specific EGF Receptor Tyrosines J. Biol. Chem., March 8, 2002; 277(11): 9405 - 9414. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sirim, L. Zeitlmann, B. Kellersch, C. S. Falk, D. J. Schendel, and W. Kolanus Calcium Signaling through the beta 2-Cytoplasmic Domain of LFA-1 Requires Intracellular Elements of the T Cell Receptor Complex J. Biol. Chem., November 9, 2001; 276(46): 42945 - 42956. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Wang, X.-F. Zhang, and J. E. Groopman Stimulation of beta 1 Integrin Induces Tyrosine Phosphorylation of Vascular Endothelial Growth Factor Receptor-3 and Modulates Cell Migration J. Biol. Chem., November 2, 2001; 276(45): 41950 - 41957. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Danilkovitch-Miagkova, A. Miagkov, A. Skeel, N. Nakaigawa, B. Zbar, and E. J. Leonard Oncogenic Mutants of RON and MET Receptor Tyrosine Kinases Cause Activation of the {beta}-Catenin Pathway Mol. Cell. Biol., September 1, 2001; 21(17): 5857 - 5868. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wang, L. D. Ferrell, S. Faouzi, J. J. Maher, and J. M. Bishop Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice J. Cell Biol., May 29, 2001; 153(5): 1023 - 1034. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |